Skip to main content
SpringerLink
Log in

Use of TIP may reduce economic burden of CF

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Novartis Pharma AG.

Reference

  • Panguluri S, et al. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis. Clinical Drug Investigation : 22 Jun 2017. Available from: URL: http://doi.org/10.1007/s40261-017-0537-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Use of TIP may reduce economic burden of CF. PharmacoEcon Outcomes News 782, 31 (2017). https://doi.org/10.1007/s40274-017-4162-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4162-x

Search

Navigation